These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 27354650)

  • 1. Safety of Emulsifying Lipid Formulation Containing Omega-3 Polyunsaturated Fatty Acids for Patients with Crohn's Disease.
    Yasueda A; Shinzaki S; Iijima H; Mizushima T; Nishimura J; Hiyama S; Ohno S; Ito T
    Anticancer Res; 2016 Jul; 36(7):3753-9. PubMed ID: 27354650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group).
    Lorenz-Meyer H; Bauer P; Nicolay C; Schulz B; Purrmann J; Fleig WE; Scheurlen C; Koop I; Pudel V; Carr L
    Scand J Gastroenterol; 1996 Aug; 31(8):778-85. PubMed ID: 8858747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease.
    Belluzzi A; Brignola C; Campieri M; Pera A; Boschi S; Miglioli M
    N Engl J Med; 1996 Jun; 334(24):1557-60. PubMed ID: 8628335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids.
    Nielsen AA; Jørgensen LG; Nielsen JN; Eivindson M; Grønbaek H; Vind I; Hougaard DM; Skogstrand K; Jensen S; Munkholm P; Brandslund I; Hey H
    Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1121-8. PubMed ID: 16305726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
    Feagan BG; Sandborn WJ; Mittmann U; Bar-Meir S; D'Haens G; Bradette M; Cohen A; Dallaire C; Ponich TP; McDonald JW; Hébuterne X; Paré P; Klvana P; Niv Y; Ardizzone S; Alexeeva O; Rostom A; Kiudelis G; Spleiss J; Gilgen D; Vandervoort MK; Wong CJ; Zou GY; Donner A; Rutgeerts P
    JAMA; 2008 Apr; 299(14):1690-7. PubMed ID: 18398081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acid for the treatment and remission of Crohn's disease.
    Swan K; Allen PJ
    J Complement Integr Med; 2013 May; 10():. PubMed ID: 23652637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saccharomyces boulardii does not prevent relapse of Crohn's disease.
    Bourreille A; Cadiot G; Le Dreau G; Laharie D; Beaugerie L; Dupas JL; Marteau P; Rampal P; Moyse D; Saleh A; Le Guern ME; Galmiche JP;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):982-7. PubMed ID: 23466709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.
    Romano C; Cucchiara S; Barabino A; Annese V; Sferlazzas C
    World J Gastroenterol; 2005 Dec; 11(45):7118-21. PubMed ID: 16437657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
    Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term study of infliximab treatment for Crohn's disease in China.
    Zheng JJ; Zhi P; Wang YM; Zhu F; Gu W; Xing YC; Zhou CL; Shen BW
    J Dig Dis; 2011 Apr; 12(2):105-9. PubMed ID: 21401895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.